Searching the Genomes of Inbred Mouse Strains for Incompatibilities That Reproductively Isolate Their Wild Relatives
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Human Chromosome‐Specific Aneuploidy Is Influenced by DNA
Article Human chromosome-specific aneuploidy is influenced by DNA-dependent centromeric features Marie Dumont1,†, Riccardo Gamba1,†, Pierre Gestraud1,2,3, Sjoerd Klaasen4, Joseph T Worrall5, Sippe G De Vries6, Vincent Boudreau7, Catalina Salinas-Luypaert1, Paul S Maddox7, Susanne MA Lens6, Geert JPL Kops4 , Sarah E McClelland5, Karen H Miga8 & Daniele Fachinetti1,* Abstract Introduction Intrinsic genomic features of individual chromosomes can contri- Defects during cell division can lead to loss or gain of chromosomes bute to chromosome-specific aneuploidy. Centromeres are key in the daughter cells, a phenomenon called aneuploidy. This alters elements for the maintenance of chromosome segregation fidelity gene copy number and cell homeostasis, leading to genomic instabil- via a specialized chromatin marked by CENP-A wrapped by repeti- ity and pathological conditions including genetic diseases and various tive DNA. These long stretches of repetitive DNA vary in length types of cancers (Gordon et al, 2012; Santaguida & Amon, 2015). among human chromosomes. Using CENP-A genetic inactivation in While it is known that selection is a key process in maintaining aneu- human cells, we directly interrogate if differences in the centro- ploidy in cancer, a preceding mis-segregation event is required. It was mere length reflect the heterogeneity of centromeric DNA-depen- shown that chromosome-specific aneuploidy occurs under conditions dent features and whether this, in turn, affects the genesis of that compromise genome stability, such as treatments with micro- chromosome-specific aneuploidy. Using three distinct approaches, tubule poisons (Caria et al, 1996; Worrall et al, 2018), heterochro- we show that mis-segregation rates vary among different chromo- matin hypomethylation (Fauth & Scherthan, 1998), or following somes under conditions that compromise centromere function. -
Absence of the ER Cation Channel TMEM38B/TRIC-B Disrupts Intracellular Calcium Homeostasis and Dysregulates Collagen Synthesis in Recessive Osteogenesis Imperfecta
RESEARCH ARTICLE Absence of the ER Cation Channel TMEM38B/TRIC-B Disrupts Intracellular Calcium Homeostasis and Dysregulates Collagen Synthesis in Recessive Osteogenesis Imperfecta Wayne A. Cabral1, Masaki Ishikawa2¤a, Matthias Garten3, Elena N. Makareeva4, Brandi M. Sargent1, MaryAnn Weis5, Aileen M. Barnes1, Emma A. Webb6,7, Nicholas J. Shaw7, Leena Ala-Kokko8, Felicitas L. Lacbawan9¤b, Wolfgang Högler6,7, Sergey Leikin4, Paul a11111 S. Blank3, Joshua Zimmerberg3, David R. Eyre5, Yoshihiko Yamada2, Joan C. Marini1* 1 Section on Heritable Disorders of Bone and Extracellular Matrix, NICHD, NIH, Bethesda, Maryland, United States of America, 2 Molecular Biology Section, NIDCR, NIH, Bethesda, Maryland, United States of America, 3 Section on Integrative Biophysics, NICHD, NIH, Bethesda, Maryland, United States of America, 4 Section on Physical Biochemistry, NICHD, NIH, Bethesda, Maryland, United States of America, 5 Department of Orthopaedics and Sports Medicine, University of Washington, Seattle, Washington, United States of America, 6 School of Clinical and Experimental Medicine, Institute of Biomedical Research, OPEN ACCESS University of Birmingham, Birmingham, United Kingdom, 7 Department of Endocrinology and Diabetes, Birmingham Children’s Hospital, Birmingham, United Kingdom, 8 Connective Tissue Gene Tests, Allentown, Citation: Cabral WA, Ishikawa M, Garten M, Pennsylvania, United States of America, 9 Department of Medical Genetics, Children’s National Medical Makareeva EN, Sargent BM, Weis M, et al. (2016) Center, Washington D.C., United States of America Absence of the ER Cation Channel TMEM38B/TRIC- B Disrupts Intracellular Calcium Homeostasis and ¤a Current address: Department of Restorative Dentistry, Division of Operative Dentistry, Tohoku University, Dysregulates Collagen Synthesis in Recessive Graduate School of Dentistry, Sendai, Japan ¤ Osteogenesis Imperfecta. -
Bioinformatics Analyses of Genomic Imprinting
Bioinformatics Analyses of Genomic Imprinting Dissertation zur Erlangung des Grades des Doktors der Naturwissenschaften der Naturwissenschaftlich-Technischen Fakultät III Chemie, Pharmazie, Bio- und Werkstoffwissenschaften der Universität des Saarlandes von Barbara Hutter Saarbrücken 2009 Tag des Kolloquiums: 08.12.2009 Dekan: Prof. Dr.-Ing. Stefan Diebels Berichterstatter: Prof. Dr. Volkhard Helms Priv.-Doz. Dr. Martina Paulsen Vorsitz: Prof. Dr. Jörn Walter Akad. Mitarbeiter: Dr. Tihamér Geyer Table of contents Summary________________________________________________________________ I Zusammenfassung ________________________________________________________ I Acknowledgements _______________________________________________________II Abbreviations ___________________________________________________________ III Chapter 1 – Introduction __________________________________________________ 1 1.1 Important terms and concepts related to genomic imprinting __________________________ 2 1.2 CpG islands as regulatory elements ______________________________________________ 3 1.3 Differentially methylated regions and imprinting clusters_____________________________ 6 1.4 Reading the imprint __________________________________________________________ 8 1.5 Chromatin marks at imprinted regions___________________________________________ 10 1.6 Roles of repetitive elements ___________________________________________________ 12 1.7 Functional implications of imprinted genes _______________________________________ 14 1.8 Evolution and parental conflict ________________________________________________ -
Laboratory Testing for Her2 Status in Breast Cancer
Laboratory Testing for Her2 Status in Breast Cancer Katherine Geiersbach, M.D. Assistant Professor, Department of Pathology May 28, 2015 Overview • Clinical relevance of Her2 status for treatment of breast cancer • Standard approaches for determining Her2 status in breast cancer • Current concepts and controversies in Her2 testing 2 Who gets breast cancer? • Breast cancer is one of the most common malignancies to affect women • About 1 in 8 women will be diagnosed with breast cancer at some point in her lifetime • Most cases of breast cancer are sporadic, but a small percentage (5-10%) are related to a heritable gene mutation, most commonly BRCA1 or BRCA2 • Having a first degree relative with breast cancer increases a woman’s chance of developing breast cancer • Screening mammography is recommended for older women – US Preventive Services Task Force: Every 2 years starting at age 50 – American Cancer Society, others: Every 2 years starting at age 40 How is breast cancer treated? • Surgery: excision with or without sentinel lymph node biopsy – Breast conserving: lumpectomy, partial mastectomy – Mastectomy • Chemotherapy: before and/or after surgery • Radiation • Targeted therapies – Hormone therapy: Tamoxifen, aromatase inhibitors – Her2 targeted therapy for cancers with overexpression of the gene ERBB2, commonly called Her2 or Her2/neu • Treatment is based on testing for ER, PR, and Her2 status, as well as cancer grade and stage. 4 Her2 targeted therapy • Herceptin (trastuzumab) • Others: pertuzumab (Perjeta), T-DM1 (Kadcyla), and lapatinib (Tykerb) • Recent data shows that a combination of pertuzumab, trastuzumab, and docetaxel (PTD) improved progression free survival compared to patients who had only trastuzumab and docetaxel (TD)1,2 source: http://www.perjeta.com/hcp/moa 1. -
16P11.2 Deletion Syndrome Guidebook
16p11.2 Deletion Syndrome Guidebook Page 1 Version 1.0, 12/11/2015 16p11.2 Deletion Syndrome Guidebook This guidebook was developed by the Simons VIP Connect Study Team to help you learn important information about living with the 16p11.2 deletion syndrome. Inside, you will find that we review everything from basic genetics and features of 16p11.2 deletion syndrome, to a description of clinical care and management considerations. - Simons VIP Connect Page 2 Version 1.0, 12/11/2015 Table of Contents How Did We Collect All of this Information? ................................................................................................ 4 What is Simons VIP Connect? ................................................................................................................... 4 What is the Simons Variation in Individuals Project (Simons VIP)? .......................................................... 5 Simons VIP Connect Research................................................................................................................... 5 Definition of 16p11.2 Deletion ..................................................................................................................... 6 What is a Copy Number Variant (CNV)? ................................................................................................... 7 Inheritance ................................................................................................................................................ 8 How is a 16p11.2 Deletion Found? .......................................................................................................... -
Hormonal Regulation of TSEI-Repressed Genes:Evidence
MOLECULAR AND CELLULAR BIOLOGY, JUlY 1989, p. 2837-2846 Vol. 9, No. 7 0270-7306/89/072837-10$02.00/0 Copyright C) 1989, American Society for Microbiology Hormonal Regulation of TSEI-Repressed Genes: Evidence for Multiple Genetic Controls in Extinction MATHEW J. THAYER AND R. E. K. FOURNIER* Department of Molecul(ar Medicine, Fred Hiutchinson Cancer Research Center, 1124 Columbia Street, Seattle, Washington 98104 Received 9 January 1989/Accepted 26 March 1989 Somatic cell hybrids formed by fusing hepatoma cells with fibroblasts generally fail to express liver functions, a phenomenon termed extinction. Previous studies demonstrated that extinction of the genes encoding tyrosine aminotransferase, phosphoenolpyruvate carboxykinase, and argininosuccinate synthetase is mediated by a specific genetic locus (TSEI) that maps to mouse chromosome 11 and human chromosome 17. In this report, we show that full repression of these genes requires a genetic factor in addition to TSE1. This conclusion is based on the observation that residual gene activity was apparent in monochromosomal hybrids retaining human TSEI but not in complex hybrids retaining many fibroblast chromosomes. Furthermore, TSE1- repressed genes were hormone inducible, whereas fully extinguished genes were not. Analysis of hybrid segregants indicated that genetic loci required for the complete repression phenotype were distinct from TSE1. Tissue-specific gene expression in mammalian cells is ing that single fibroblast chromosome are extinguished for primarily regulated at the level of transcription (8). A par- both serum albumin and alcohol dehydrogenase gene activ- ticular gene may account for a large fraction of total tran- ity (A. C. Chin and R. E. K. Fournier, submitted for publi- scription in one cell type yet be virtually silent in other cell cation). -
134 Mb (Almost the Same As the Size of Chromosome 10). It Is ~4–4.5% of the Total Human Genome
Chromosome 11 ©Chromosome Disorder Outreach Inc. (CDO) Technical genetic content provided by Dr. Iosif Lurie, M.D. Ph.D Medical Geneticist and CDO Medical Consultant/Advisor. Ideogram courtesy of the University of Washington Department of Pathology: ©1994 David Adler.hum_11.gif Introduction The genetic size of chromosome 11 is ~134 Mb (almost the same as the size of chromosome 10). It is ~4–4.5% of the total human genome. The length of its short arm is ~50 Mb; the length of its long arm in ~84 Mb. Chromosome 11 is a very gene–rich area. It contains ~1,500 genes. Mutations of ~200 of these genes are known to cause birth defects or some functional abnormalities. The short arm of chromosome 11 contains a region which is known to be imprinted. As a result duplications of this region will have different manifestations depending on the sex of the parent responsible for this defect. Phenotypes of persons with duplications of the maternal origin will be different from the phenotypes of the persons with a paternal duplication of the same area. There are ~1,400 patients with different structural abnormalities of chromosome 11 as the only abnormality or in association with abnormalities for other chromosomes. At least 800 of these patients had different deletions of chromosome 11. Deletions of the short arm have been reported in ~250 patients (including those with an additional imbalance); deletions of the long arm have been described in ~550 patients. There are two syndromes caused by deletions of the short arm (both of these syndromes have been known for several years) and one well–known syndrome caused by distal deletions of the long arm (Jacobsen syndrome). -
Gene Expression During Normal and FSHD Myogenesis Tsumagari Et Al
Gene expression during normal and FSHD myogenesis Tsumagari et al. Tsumagari et al. BMC Medical Genomics 2011, 4:67 http://www.biomedcentral.com/1755-8794/4/67 (27 September 2011) Tsumagari et al. BMC Medical Genomics 2011, 4:67 http://www.biomedcentral.com/1755-8794/4/67 RESEARCHARTICLE Open Access Gene expression during normal and FSHD myogenesis Koji Tsumagari1, Shao-Chi Chang1, Michelle Lacey2,3, Carl Baribault2,3, Sridar V Chittur4, Janet Sowden5, Rabi Tawil5, Gregory E Crawford6 and Melanie Ehrlich1,3* Abstract Background: Facioscapulohumeral muscular dystrophy (FSHD) is a dominant disease linked to contraction of an array of tandem 3.3-kb repeats (D4Z4) at 4q35. Within each repeat unit is a gene, DUX4, that can encode a protein containing two homeodomains. A DUX4 transcript derived from the last repeat unit in a contracted array is associated with pathogenesis but it is unclear how. Methods: Using exon-based microarrays, the expression profiles of myogenic precursor cells were determined. Both undifferentiated myoblasts and myoblasts differentiated to myotubes derived from FSHD patients and controls were studied after immunocytochemical verification of the quality of the cultures. To further our understanding of FSHD and normal myogenesis, the expression profiles obtained were compared to those of 19 non-muscle cell types analyzed by identical methods. Results: Many of the ~17,000 examined genes were differentially expressed (> 2-fold, p < 0.01) in control myoblasts or myotubes vs. non-muscle cells (2185 and 3006, respectively) or in FSHD vs. control myoblasts or myotubes (295 and 797, respectively). Surprisingly, despite the morphologically normal differentiation of FSHD myoblasts to myotubes, most of the disease-related dysregulation was seen as dampening of normal myogenesis- specific expression changes, including in genes for muscle structure, mitochondrial function, stress responses, and signal transduction. -
The KMT1A-GATA3-STAT3 Circuit Is a Novel Self-Renewal Signaling of Human Bladder Cancer Stem Cells Zhao Yang1, Luyun He2,3, Kais
The KMT1A-GATA3-STAT3 circuit is a novel self-renewal signaling of human bladder cancer stem cells Zhao Yang1, Luyun He2,3, Kaisu Lin4, Yun Zhang1, Aihua Deng1, Yong Liang1, Chong Li2, 5, & Tingyi Wen1, 6, 1CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China 2Core Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China 3CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China 4Department of Oncology, the Second Affiliated Hospital of Soochow University, Suzhou 215000, China 5Beijing Jianlan Institute of Medicine, Beijing 100190, China 6Savaid Medical School, University of Chinese Academy of Sciences, Beijing 100049, China Correspondence author: Tingyi Wen, e-mail: [email protected] Chong Li, e-mail: [email protected] Supplementary Figure S1. Isolation of human bladder cancer stem cells. BCMab1 and CD44 were used to isolate bladder cancer stem cells (BCSCs: BCMab1+CD44+) and bladder cancer non-stem cells (BCNSCs: BCMab1-CD44-) from EJ, samples #1 and #2 by flow cytometry. Supplementary Figure S2. Gene ontology analysis of downregulated genes of human BCSCs. (A) Pathway enrichment of 103 downregulated genes in BCSCs. (B) The seven downregulated genes in BCSCs participating in centromeric heterochromatin, mRNA-3’-UTR binding and translation regulator activity signaling pathways were validated by qRT-PCR. Data are presented as mean ± SD. P < 0.05; P < 0.01. Supplementary Figure S3. The expression of KMT1A is higher in human BC than that in peri-tumor tissues. (A) The expression of KMT1A was higher in BC samples than that in peri-tumors as assessed by immunohistochemistry, Scale bar = 50 m. -
Osteogenesis Imperfecta
Osteogenesis imperfecta Description Osteogenesis imperfecta (OI) is a group of genetic disorders that mainly affect the bones. The term "osteogenesis imperfecta" means imperfect bone formation. People with this condition have bones that break (fracture) easily, often from mild trauma or with no apparent cause. Multiple fractures are common, and in severe cases, can occur even before birth. Milder cases may involve only a few fractures over a person's lifetime. There are at least 19 recognized forms of osteogenesis imperfecta, designated type I through type XIX. Several types are distinguished by their signs and symptoms, although their characteristic features overlap. Increasingly, genetic causes are used to define rarer forms of osteogenesis imperfecta. Type I (also known as classic non- deforming osteogenesis imperfecta with blue sclerae) is the mildest form of osteogenesis imperfecta. Type II (also known as perinatally lethal osteogenesis imperfecta) is the most severe. Other types of this condition, including types III ( progressively deforming osteogenesis imperfecta) and IV (common variable osteogenesis imperfecta with normal sclerae), have signs and symptoms that fall somewhere between these two extremes. The milder forms of osteogenesis imperfecta, including type I, are characterized by bone fractures during childhood and adolescence that often result from minor trauma, such as falling while learning to walk. Fractures occur less frequently in adulthood. People with mild forms of the condition typically have a blue or grey tint to the part of the eye that is usually white (the sclera), and about half develop hearing loss in adulthood. Unlike more severely affected individuals, people with type I are usually of normal or near normal height. -
Blueprint Genetics Comprehensive Growth Disorders / Skeletal
Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders Panel Test code: MA4301 Is a 374 gene panel that includes assessment of non-coding variants. This panel covers the majority of the genes listed in the Nosology 2015 (PMID: 26394607) and all genes in our Malformation category that cause growth retardation, short stature or skeletal dysplasia and is therefore a powerful diagnostic tool. It is ideal for patients suspected to have a syndromic or an isolated growth disorder or a skeletal dysplasia. About Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders This panel covers a broad spectrum of diseases associated with growth retardation, short stature or skeletal dysplasia. Many of these conditions have overlapping features which can make clinical diagnosis a challenge. Genetic diagnostics is therefore the most efficient way to subtype the diseases and enable individualized treatment and management decisions. Moreover, detection of causative mutations establishes the mode of inheritance in the family which is essential for informed genetic counseling. For additional information regarding the conditions tested on this panel, please refer to the National Organization for Rare Disorders and / or GeneReviews. Availability 4 weeks Gene Set Description Genes in the Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders Panel and their clinical significance Gene Associated phenotypes Inheritance ClinVar HGMD ACAN# Spondyloepimetaphyseal dysplasia, aggrecan type, AD/AR 20 56 Spondyloepiphyseal dysplasia, Kimberley -
Visualization and Exploration of Transcriptomics Data Nils Gehlenborg
Visualization and Exploration of Transcriptomics Data 05 The identifier 800 year identifier Nils Gehlenborg Sidney Sussex College To celebrate our 800 year history an adaptation of the core identifier has been commissioned. This should be used on communications in the time period up to and including 2009. The 800 year identifier consists of three elements: the shield, the University of Cambridge logotype and the 800 years wording. It should not be redrawn, digitally manipulated or altered. The elements should not be A dissertation submitted to the University of Cambridge used independently and their relationship should for the degree of Doctor of Philosophy remain consistent. The 800 year identifier must always be reproduced from a digital master reference. This is available in eps, jpeg and gif format. Please ensure the appropriate artwork format is used. File formats European Molecular Biology Laboratory, eps: all professionally printed applications European Bioinformatics Institute, jpeg: Microsoft programmes Wellcome Trust Genome Campus, gif: online usage Hinxton, Cambridge, CB10 1SD, Colour United Kingdom. The 800 year identifier only appears in the five colour variants shown on this page. Email: [email protected] Black, Red Pantone 032, Yellow Pantone 109 and white October 12, 2010 shield with black (or white name). Single colour black or white. Please try to avoid any other colour combinations. Pantone 032 R237 G41 B57 Pantone 109 R254 G209 B0 To Maureen. This dissertation is my own work and contains nothing which is the outcome of work done in collaboration with others, except as specified in the text and acknowledgements. This dissertation is not substantially the same as any I have submit- ted for a degree, diploma or other qualification at any other university, and no part has already been, or is currently being submitted for any degree, diploma or other qualification.